Resultado de búsqueda
Hace 6 horas · EMERYVILLE, Calif., June 7, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that it will host a sponsored symposium to ...
Hace 6 horas · The symposium titled "Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond" will take place on June 14, 2024, from 8:15 a.m. to 9:30 a.m. CEST. The symposium will offer ...
Hace 19 horas · Dr. Gerhard Krönke, University of Erlangen-Nuremberg, Germany. ... Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune disease: ...
Hace 19 horas · The symposium titled "Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond" will take place on June 14, 2024, from 8:15 a.m. to 9:30 a.m. CEST. The symposium will offer ...
Hace 19 horas · Kyverna Therapeutics will present data on the largest set of patients treated with KYV-101, an anti-CD19 CAR T-cell therapy, at EULAR 2024. The data covers 50 patients from more than 15 centers in the US and Europe, addressing 12 indications.
Hace 19 horas · Fully motorised C-arm system can be operated in sterile field by remote control Precise and automated positioning for up to 50 per cent faster intraoperative imaging Relief of staff and reduction of idle time in the operating theatre Siemens Healthineers has developed an automated, self-driving C-arm system for intraoperative imaging in surgery. Equipped with holonomic, omnidirectional wheels ...
Hace 19 horas · A press conference will be hosted later in the day featuring Georg Schett, M.D., vice president of research at the Friedrich-Alexander-University in Erlangen, Germany , and Peter A. Merkel , M.D., M.P.H. Both are members of Kyverna's Scientific Advisory Board.
